Caves: Clinical Trials

3 trials of Caves, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting, 1 completed, 1 terminated. 3 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 23Active not recruiting 1, Completed 1, Terminated 1
Phase 11Terminated 1

Follow Caves: new trials by email Literature Review of Caves trials Research Report on Caves

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer
EP0057, olaparib, CT scan - Urothelial Carcinoma, Urothelial Cancer
Phase 1 / Phase 2TerminatedNational Cancer Institute (NCI)452016-05-092026-08-13
Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia
Cladribine, Rituximab, BMbx - Hairy Cell Leukemia
Phase 2Active not recruitingNational Cancer Institute (NCI)1752008-10-202026-08-18
Treatment and Natural History Study of Lymphomatoid Granulomatosis
Interferon, Rituxan and EPOCH, Tumor biopsy - Lymphomatoid Granulomatosis, Granulomatosis, Lymphomatoid
Phase 2CompletedNational Cancer Institute (NCI)941995-05-052025-06-19

Conditions studied

Carcinoma, Transitional Cell (1)  ·  Epstein-Barr Virus Infections (1)  ·  Leukemia (1)  ·  Leukemia, Hairy Cell (1)  ·  Lung Neoplasms (1)  ·  Lymphoma (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Lymphomatoid Granulomatosis (1)  ·  Lymphoproliferative Disorders (1)  ·  Neoplasm, Residual (1)  ·  Prostatic Neoplasms (1)  ·  Small Cell Lung Carcinoma (1)

Sponsors

National Cancer Institute (NCI) (3)

Countries

United States (3)

Top investigators

Anish Thomas, M.D. (1)  ·  Christopher J Melani, M.D. (1)  ·  Robert J Kreitman, M.D. (1)

Results publications

PMID 32109194, PMID 32897402, PMID 34607348, PMID 37011643, PMID 42820295